2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease

US9663502B2 · kind B2 · utility

Assignees

• Lycera Corporation · US
• Merck Sharp & Dohme LLC · US

Inventors

• Thomas D. Aicher · Ann Arbor, US
• Chad A. VanHuis · Hartland, US
• John MacLean · Brookline, US
• Brian M. Andresen · Sharon, US
• Kenneth J. Barr · San Francisco, US
• Corey E. Bienstock · Natick, US
• Neville J. Anthony · Hatfield, US
• Matthew H. Daniels · Somerville, US
• Yuan Liu · Billerica, US
• Catherine White · Newton, US
• Blair T. Lapointe · Brookline, US
• Nunzio Sciammetta · Sudbury, US
• Vladimir Simov · Boston, US
• Wesley B. Trotter · Boston, US
• Kun Liu · Edison, US

Key dates

• Filing date: Dec 19, 2014
• Grant date: May 30, 2017
• Expiry date: Dec 19, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, Ra, Rb, Rc, Rd, Rg, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.